● SK chemicals Enter into Agreement with Daewoong Pharmaceutical for Joint Marketing and Sales of Sky Zoster to Expand the Market of Herpes Zoster Vaccine
- A blockbuster medicine which has been sold more than KRW 10 billion cumulatively this year is expected to show increases in sales as its vaccination market expands.
- Joint marketing and sales with Daewoong Pharmaceutical will help SK chemicals achieve 50% of the market share this year.
The first domestically developed herpes zoster vaccine “Sky Zoster,” which has become a blockbuster medicine as its cumulative sales exceeded KRW 10 billion this year, jumped to boost its sale.
SK chemicals (CEO Park Mahn-hoon) announced on May 10 that it has entered into an agreement with Daewoong Pharmaceutical for joint marketing and sales of the herpes zoster vaccine “Sky Zoster.”
Thanks to this agreement, SK chemicals and Daewoong Pharmaceutical will jointly conduct sales and marketing activities of Sky Zoster at hospitals and clinics around the country starting this month.
Daewoong Pharmaceutical is planning to capitalize on its stable infrastructure for sales and marketing at general hospitals and private clinics to contribute to improving the convenience of patients and expanding the domestic market of herpes zoster vaccine.
Sky Zoster, a herpes zoster vaccine that was developed for the second time in the world and for the first time in Korea last December, is a live vaccine which is generated by attenuating the Varicella Zoster Virus. Overseas professional non-clinical testing agencies strictly verified its safety, conducted clinical studies in Korea for about 5 years and proved its efficacy and safety.
SK chemicals aims to stably supply Sky Zoster, which has been quickly and successfully launched in the market, by providing the vaccine at various hospitals and clinics, and achieve its market share to 50% in the first year of launch.
Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said “Daewoong Pharmaceutical will use its differentiated marketing approach with our four steps of verification and our competitive sales force to create a synergy effect in expanding the market share of “Sky Zoster,” an excellent vaccine, and contribute to improving the quality of life of citizens.”
“As Korea is becoming an aging society, the demands for the herpes zoster vaccine are steadily increasing,” said Ahn Jae-yong, head of the vaccine business division of SK chemicals. “We will penetrate into the market, which has been dominated by global pharmaceutical companies, by stably supplying this domestic vaccine.”
Meanwhile, SK chemicals is planning to split off its vaccine business division on July 1 to reinforce its business expertise and enhance its management efficiency.
Photo: Ahn Jae-yong, head of the vaccine business division of SK chemicals (right in the photograph) and Jeon Seung-ho, CEO of Daewoong Pharmaceutical, are signing an agreement for joint sales of Sky Zoster.